Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.

Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, Lai M, Wesenberg A, Ugaonkar S, Levendosky K, Mizenina O, Kleinbeck K, Lifson JD, Peet MM, Lloyd Z, Benson M, Heneine W, O'Keefe BR, Robbiani M, Martinelli E, Grasperge B, Blanchard J, Gettie A, Teleshova N, Fernández-Romero JA, Zydowsky TM.

Nat Commun. 2018 Sep 24;9(1):3881. doi: 10.1038/s41467-018-06349-0.

2.

A fresh look at an old problem.

Zydowsky TM.

Lancet Infect Dis. 2017 Dec;17(12):1228-1230. doi: 10.1016/S1473-3099(17)30493-0. Epub 2017 Aug 23. No abstract available.

3.

MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1.

Mizenina O, Hsu M, Jean-Pierre N, Aravantinou M, Levendosky K, Paglini G, Zydowsky TM, Robbiani M, Fernández-Romero JA.

Drug Deliv Transl Res. 2017 Dec;7(6):859-866. doi: 10.1007/s13346-017-0421-4.

PMID:
28812250
4.

An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.

Derby N, Aravantinou M, Kenney J, Ugaonkar SR, Wesenberg A, Wilk J, Kizima L, Rodriguez A, Zhang S, Mizenina O, Levendosky K, Cooney ML, Seidor S, Gettie A, Grasperge B, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero J, Zydowsky TM, Robbiani M.

Drug Deliv Transl Res. 2017 Dec;7(6):840-858. doi: 10.1007/s13346-017-0389-0.

5.

MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.

Calenda G, Villegas G, Barnable P, Litterst C, Levendosky K, Gettie A, Cooney ML, Blanchard J, Fernández-Romero JA, Zydowsky TM, Teleshova N.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e67-e74. doi: 10.1097/QAI.0000000000001167.

6.

First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.

Friedland BA, Hoesley CJ, Plagianos M, Hoskin E, Zhang S, Teleshova N, Alami M, Novak L, Kleinbeck KR, Katzen LL, Zydowsky TM, Fernández-Romero JA, Creasy GW.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496.

7.

A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.

Villegas G, Calenda G, Ugaonkar S, Zhang S, Kizima L, Mizenina O, Gettie A, Blanchard J, Cooney ML, Robbiani M, Fernández-Romero JA, Zydowsky TM, Teleshova N.

PLoS One. 2016 Jul 18;11(7):e0159332. doi: 10.1371/journal.pone.0159332. eCollection 2016.

8.

In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa.

Villegas G, Calenda G, Zhang S, Mizenina O, Kleinbeck K, Cooney ML, Hoesley CJ, Creasy GW, Friedland B, Fernández-Romero JA, Zydowsky TM, Teleshova N.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5459-66. doi: 10.1128/AAC.00392-16. Print 2016 Sep.

9.

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations.

Jean-Pierre N, Barnable P, Kizima L, Rodríguez A, Seidor S, Cooney ML, Clark MR, Doncel GF, Robbiani M, Zydowsky TM, Teleshova N, Fernández-Romero JA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):1141-4. doi: 10.1128/AAC.02468-15. Print 2016 Feb.

10.

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.

Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, Kleinbeck K, Bonnaire T, Robbiani M, Zydowsky TM, O'Keefe BR, Fernández-Romero JA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7290-8. doi: 10.1128/AAC.01816-15. Epub 2015 Sep 14.

11.

A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.

Ugaonkar SR, Wesenberg A, Wilk J, Seidor S, Mizenina O, Kizima L, Rodriguez A, Zhang S, Levendosky K, Kenney J, Aravantinou M, Derby N, Grasperge B, Gettie A, Blanchard J, Kumar N, Roberts K, Robbiani M, Fernández-Romero JA, Zydowsky TM.

J Control Release. 2015 Sep 10;213:57-68. doi: 10.1016/j.jconrel.2015.06.018. Epub 2015 Jun 17.

12.

MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.

Barnable P, Calenda G, Bonnaire T, Menon R, Levendosky K, Gettie A, Blanchard J, Cooney ML, Fernández-Romero JA, Zydowsky TM, Teleshova N.

Antimicrob Agents Chemother. 2015 Jul;59(7):3829-37. doi: 10.1128/AAC.00073-15. Epub 2015 Apr 13.

13.

Preclinical assessments of vaginal microbicide candidate safety and efficacy.

Fernández-Romero JA, Teleshova N, Zydowsky TM, Robbiani M.

Adv Drug Deliv Rev. 2015 Sep 15;92:27-38. doi: 10.1016/j.addr.2014.12.005. Epub 2014 Dec 24. Review.

14.

Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides.

Kenney J, Derby N, Aravantinou M, Kleinbeck K, Frank I, Gettie A, Grasperge B, Blanchard J, Piatak M Jr, Lifson JD, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1117-24. doi: 10.1089/aid.2014.0207.

15.

A MIV-150/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explants.

Barnable P, Calenda G, Ouattara L, Gettie A, Blanchard J, Jean-Pierre N, Kizima L, Rodríguez A, Abraham C, Menon R, Seidor S, Cooney ML, Roberts KD, Sperling R, Piatak M Jr, Lifson JD, Fernandez-Romero JA, Zydowsky TM, Robbiani M, Teleshova N.

PLoS One. 2014 Sep 26;9(9):e108109. doi: 10.1371/journal.pone.0108109. eCollection 2014.

16.

A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV.

Kizima L, Rodríguez A, Kenney J, Derby N, Mizenina O, Menon R, Seidor S, Zhang S, Levendosky K, Jean-Pierre N, Pugach P, Villegas G, Ford BE, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Teleshova N, Zydowsky TM, Robbiani M, Fernández-Romero JA.

PLoS One. 2014 Apr 16;9(4):e94547. doi: 10.1371/journal.pone.0094547. eCollection 2014.

17.

MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.

Ouattara LA, Barnable P, Mawson P, Seidor S, Zydowsky TM, Kizima L, Rodriguez A, Fernández-Romero JA, Cooney ML, Roberts KD, Gettie A, Blanchard J, Robbiani M, Teleshova N.

Antimicrob Agents Chemother. 2014 May;58(5):2841-8. doi: 10.1128/AAC.01529-13. Epub 2014 Mar 10.

18.

Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques.

Hsu M, Keele BF, Aravantinou M, Krawczyk N, Seidor S, Abraham CJ, Zhang S, Rodriguez A, Kizima L, Derby N, Jean-Pierre N, Mizenina O, Gettie A, Grasperge B, Blanchard J, Piatak MJ Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

PLoS One. 2014 Feb 27;9(2):e89300. doi: 10.1371/journal.pone.0089300. eCollection 2014.

19.

A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.

Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, Kenney J, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):174-83. doi: 10.1089/AID.2013.0165. Epub 2013 Nov 22.

20.

A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.

Kenney J, Rodríguez A, Kizima L, Seidor S, Menon R, Jean-Pierre N, Pugach P, Levendosky K, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Zydowsky TM, Robbiani M, Fernández Romero JA.

Antimicrob Agents Chemother. 2013 Aug;57(8):4001-9. doi: 10.1128/AAC.00796-13. Epub 2013 Jun 10.

21.

An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques.

Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM.

Sci Transl Med. 2012 Sep 5;4(150):150ra123. doi: 10.1126/scitranslmed.3003936.

22.

The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.

Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham CJ, Menon R, Seidor S, Goldman D, Kenney J, Villegas G, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Teleshova N, Robbiani M.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1467-75. doi: 10.1089/AID.2012.0080. Epub 2012 Aug 27.

23.

A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.

Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, Menon R, Seidor S, Zhang S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1476-84. doi: 10.1089/AID.2012.0087. Epub 2012 Jul 30.

24.

Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM.

Antimicrob Agents Chemother. 2012 Jan;56(1):358-68. doi: 10.1128/AAC.05461-11. Epub 2011 Nov 7.

25.

Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators.

Katzen LL, Fernández-Romero JA, Sarna A, Murugavel KG, Gawarecki D, Zydowsky TM, Mensch BS.

Sex Transm Dis. 2011 Nov;38(11):1050-5. doi: 10.1097/OLQ.0b013e31822e6160.

26.

The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques.

Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M.

J Virol. 2011 Jun;85(11):5504-12. doi: 10.1128/JVI.02422-10. Epub 2011 Mar 16.

27.

An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.

Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, Kizima L, Abraham CJ, Menon R, Seidor S, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M.

PLoS One. 2011 Jan 5;6(1):e15835. doi: 10.1371/journal.pone.0015835.

28.

A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, Kenney J, Piatak M, Lifson JD, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Blanchard J, Gettie A, Robbiani M.

PLoS One. 2009 Nov 30;4(11):e8060. doi: 10.1371/journal.pone.0008060.

29.

Microbicides: chemistry, structure, and strategy.

Zydowsky TM.

Curr Opin HIV AIDS. 2008 Sep;3(5):548-53. doi: 10.1097/COH.0b013e32830ab9dd.

PMID:
19373020
30.

Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity.

Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M.

PLoS One. 2008 Sep 8;3(9):e3162. doi: 10.1371/journal.pone.0003162.

31.
33.

Cardiovascular effects of orally administered ABBOTT-81988, an angiotensin II antagonist, in conscious spontaneously hypertensive rats.

Lee JY, Warner RB, Brune ME, Adler AL, Winn M, De B, Zydowsky TM, Opgenorth TJ, Kerkman DJ, DeBernardis JF.

Am J Hypertens. 1994 Nov;7(11):975-83.

PMID:
7848624
34.

Receptor interactions of Abbott-81988, a highly potent, non-peptide angiotensin-II antagonist selective for type-1 receptors.

Hancock AA, Buckner SA, Lee JY, Brune M, Morse PA, Oheim K, Warner RB, Winn M, Zydowsky TM, De B, et al.

J Recept Res. 1994 May;14(3-4):229-49.

PMID:
8083867
35.

Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat.

Lee JY, Buckner SA, Brune ME, Warner RB, Winn M, De B, Zydowsky TM, Opgenorth TJ, Kerkman DJ, Debernardis JF.

J Pharmacol Exp Ther. 1994 Jan;268(1):427-33.

PMID:
8301584
36.

2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.

Winn M, De B, Zydowsky TM, Altenbach RJ, Basha FZ, Boyd SA, Brune ME, Buckner SA, Crowell D, Drizin I, et al.

J Med Chem. 1993 Sep 3;36(18):2676-88.

PMID:
8410980
37.

Antihypertensive activity of ABBOTT-81282, a nonpeptide angiotensin II antagonist, in the renal hypertensive rat.

Lee JY, Brune ME, Warner RB, Buckner SB, Winn M, De B, Zydowsky TM, Opgenorth TJ, Kerkman DJ, DeBernardis JF.

Pharmacology. 1993 Sep;47(3):176-87.

PMID:
8415868
38.

Pharmacological characterization of Abbott-81282, a novel, non-peptide angiotensin-II antagonist selective for type-1 receptors.

Hancock AA, Buckner SA, Lee JY, Brune M, Morse PA, Oheim K, Warner RB, Winn M, Zydowsky TM, De B, et al.

Life Sci. 1993;53(11):929-37.

PMID:
8366760
39.

Discovery of a novel class of orally active, non-peptide angiotensin II antagonists.

De B, Winn M, Zydowsky TM, Kerkman DJ, DeBernardis JF, Lee J, Buckner S, Warner R, Brune M, Hancock A, et al.

J Med Chem. 1992 Oct 2;35(20):3714-7. No abstract available.

PMID:
1433184

Supplemental Content

Loading ...
Support Center